Lisata Therapeutics acquires Marea and raises $225m in concurrent PIPE
Lisata Therapeutics has completed the acquisition of Marea Therapeutics and simultaneously closed a $225 million Series C preferred stock private placement, reorienting the Nasdaq-listed company away from oncology and toward cardioendocrine diseases. Both transactions were announced on 17 September 2026.
The acquisition was structured as a stock-for-stock exchange. Marea shareholders received a combination of Lisata common stock and Series C non-voting convertible preferred stock representing, on an as-converted basis, approximately 59.5% of the combined company. Investors in the concurrent placement will hold around 38.1%, leaving legacy Lisata shareholders with roughly 2.4% of the fully diluted share count, a near-total dilution of the pre-existing equity base.
The pipeline
Marea brings two clinical-stage monoclonal antibody programmes. MAR001 is an anti-ANGPTL4 antibody in Phase 2b for severe hypertriglyceridaemia (sHTG), a metabolic condition in which persistently elevated triglycerides raise the risk of acute pancreatitis and a cluster of cardiometabolic comorbidities. A half-life-extended successor, MAR005, is the planned Phase 3 candidate. MAR002 is an allosteric growth hormone receptor antagonist antibody being developed for acromegaly, an orphan condition affecting approximately 30,000 patients in the United States, and is advancing into Phase 2. Topline Phase 2b data for MAR001 and Phase 2 proof-of-concept data for MAR002 are both expected in the fourth quarter of 2027.
Josh Lehrer, newly appointed president and chief operating officer of the combined company and former chief executive of Marea, said the transaction gives the antibody programmes "a faster path to patients who today have limited options for these serious cardioendocrine diseases."
The $225 million raise was oversubscribed and drew a notable syndicate including RA Capital Management, Third Rock Ventures, Forbion, Perceptive Advisors, Sofinnova Investments, Omega Funds, Surveyor Capital and Columbia Threadneedle Investments, among others. Net proceeds will be directed primarily toward advancing MAR001/005 and MAR002 through their next clinical milestones, with the company projecting cash runway into 2028.
Market context and competitive read-across
The sHTG space has attracted considerable therapeutic interest following setbacks and delays for earlier RNA-interference approaches, and ANGPTL4 inhibition represents a genetically validated mechanism: loss-of-function variants in ANGPTL4 are associated with lower triglycerides and reduced cardiovascular risk in large human genetics datasets. Whether an antibody can replicate the magnitude of effect seen pharmacologically remains a key question the Phase 2b readout must answer.
The acromegaly market is smaller but well-defined. Pegvisomant, the existing growth hormone receptor antagonist, requires daily subcutaneous injection; a long-acting antibody format could offer a meaningful dosing advantage if MAR002's duration of action translates from Phase 1 healthy-volunteer data into the patient population.
For Lisata itself, the pivot is stark. The company's legacy asset, certepetide, a cyclic peptide designed to enhance tumour penetration, is not abandoned outright: chief executive David Mazzo noted the company will continue to evaluate next steps for certepetide in parallel. In practice, however, the capital allocation and management bandwidth are now overwhelmingly weighted toward the Marea portfolio, and investors in the placement are buying primarily into the cardioendocrine thesis.
The transaction requires Lisata stockholder approval for conversion of the Series C preferred stock into common shares, with a meeting to be scheduled in due course. H.C. Wainwright advised Lisata; Leerink Partners advised Marea.